[ATOS] Atossa Genetics Inc.


Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.38 Change: -0.02 (-1.43%)
Ext. hours: Change: 0 (0%)

chart ATOS

Refresh chart

Strongest Trends Summary For ATOS

ATOS is in the long-term down -100% below S&P in 9 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Atossa Genetics, Inc. operates as a healthcare company that focuses on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer in the United States. Its diagnostic tests include the ForeCYTE Breast Health Test, which provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65; and the ArgusCYTE Breast Health Test that offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company also intends to offers FullCYTE Breast Health Test, which is in development to assess the individual breast ducts for pre-cancerous changes in women; and NextCYTE Breast Cancer Test that is in the prevalidation phase to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. Atossa Genetics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-2.28 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 18630% Sales Growth - Q/Q283.03% P/E-0.22
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-112.88% ROE-151.51% ROI
Current Ratio3.26 Quick Ratio3.23 Long Term Debt/Equity Debt Ratio0.34
Gross Margin Operating Margin-653.31% Net Profit Margin-656.04% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities4.29 M Cash From Investing Activities-70 K Cash From Operating Activities-3 M Gross Profit670 K
Net Profit-3.34 M Operating Profit-3.28 M Total Assets13.8 M Total Current Assets11.37 M
Total Current Liabilities3.49 M Total Debt110 K Total Liabilities3.52 M Total Revenue1.87 M
Technical Data
High 52 week7.07 Low 52 week0.92 Last close2.54 Last change0.79%
RSI29.7 Average true range0.16 Beta0.87 Volume177.7 K
Simple moving average 20 days-11.13% Simple moving average 50 days-18.15% Simple moving average 200 days31.2%
Performance Data
Performance Week-1.93% Performance Month-3.05% Performance Quart68.21% Performance Half96.9%
Performance Year-49.34% Performance Year-to-date149.02% Volatility daily6.28% Volatility weekly14.04%
Volatility monthly28.78% Volatility yearly99.7% Relative Volume171.06% Average Volume3.09 M
New High New Low


2019-10-16 08:30:00 | Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology

2019-10-15 08:30:00 | Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia

2019-09-30 08:30:00 | Atossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral Endoxifen

2019-09-06 08:30:00 | Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference

2019-09-03 08:00:00 | Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen Tablet

2019-08-13 13:26:06 | Atossa Genetics Announces Second Quarter 2019 Financial Results and Provides Company Update

2019-07-30 08:30:00 | Atossa Genetics CEO Steven Quay Gives Tedx Talk At University of Washington Regarding the the Relationship of Dense Breast Tissue and Breast Cancer Risk

2019-07-17 08:30:00 | Atossa Genetics Provides Information on FDA Expanded Access Policy and Requests

2019-07-11 08:30:00 | Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated

2019-06-28 11:38:23 | A Look At Benzinga Pro's Most-Searched Tickers For June 28, 2019

2019-06-27 08:00:00 | Atossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density

2019-06-19 15:56:16 | Some Atossa Genetics NASDAQ:ATOS Shareholders Have Copped A 99% Share Price Wipe Out

2019-05-30 08:00:00 | Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019

2019-05-13 17:21:57 | Atossa Genetics Announces First Quarter 2019 Financial Results and Provides Company Update

2019-04-30 06:10:00 | _The Digital Economy & World Markets_

2019-04-25 12:00:00 | Atossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit

2019-04-22 08:45:00 | Reducing This Amino Acid May Aid In Fight Against Breast Cancer

2019-04-22 08:30:00 | Atossa Genetics to Present at the 4th Annual Precision: Breast Cancer World R&D Summit April 25, 2019

2019-03-28 16:30:00 | Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update

2019-03-27 10:15:00 | _Bull Market Hopping?_

2019-03-26 08:30:00 | Atossa Genetics Announces Institutional Review Board Approval of Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

2019-03-18 08:30:00 | Atossa Genetics Announces Receipt of $10 Million

2019-03-14 13:01:36 | What Type Of Shareholder Owns Atossa Genetics Inc.’s NASDAQ:ATOS?

2019-03-14 12:53:31 | Atossa Genetics News: FDA Approval Sends ATOS Stock Skyrocketing

2019-03-14 08:30:00 | Atossa Genetics Announces FDA Approval of Oral Endoxifen for “Expanded Access” as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

2019-02-27 06:05:00 | _On Fed's Wings_ Vista Partners Publishes February 2019's Macroeconomic & Investment Monthly Newsletter

2019-02-07 08:30:00 | Atossa Genetics Reports Results From “Expanded Access” Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability Issues

2019-02-04 08:30:00 | Atossa Genetics Provides Breast Cancer Prevention Recommendations to the United States Preventative Services Task Force

2019-01-30 09:15:00 | Vista Partners January 2019 Monthly Macroeconomic and Investment Newsletter

2019-01-28 08:00:00 | Atossa Genetics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2019

2019-01-09 11:58:00 | 4 Healthcare Stocks Looking To Set January Highs

2019-01-09 08:35:48 | Atossa Genetics Announces Successful Completion and Final Results from Male Phase 1 Study of Topical Endoxifen

2018-12-28 07:20:00 | Detailed Research: Economic Perspectives on American Airlines Group, Sandstorm Gold, Kala Pharmaceuticals, Adecoagro S.A, Novagold Resources, and Atossa Genetics — What Drives Growth in Today's Competitive Landscape

2018-12-19 08:05:00 | _The Roller Coaster Ride Continues_

2018-12-07 12:07:13 | Edison issues outlook on Atossa Genetics ATOS

2018-12-03 08:00:00 | Atossa Genetics Announces FDA Approval  of Endoxifen for “Expanded Access” as Preoperative Systemic Endocrine Therapy for a U.S. Breast Cancer Patient

2018-11-21 08:05:00 | ''A Spate of Factors'' Vista Partners November 2018 Macro Economic and Investment Newsletter

2018-11-13 16:10:00 | Atossa Genetics Announces Third Quarter 2018 Financial Results And Provides Company Update

2018-10-25 09:10:00 | Report: Exploring Fundamental Drivers Behind Atossa Genetics, Titan International, Olympic Steel, L Brands, Sysco, and TiVo — New Horizons, Emerging Trends, and Upcoming Developments

2018-10-18 16:00:00 | _...Amidst Market Volatility_ Vista Partners' October Macroeconomic & Investment Monthly Newsletter

2018-10-11 08:00:00 | Atossa Genetics Completes Enrollment in Phase 2 Study of Topical Endoxifen in Women with Mammographic Breast Density

2018-09-26 09:05:00 | ''Superfirms' Domination Influences Economic Factors''

2018-09-25 08:20:00 | Report: Developing Opportunities within Crocs, NetApp, Gannett Co., Atossa Genetics, Omega Flex, and Lithia Motors — Future Expectations, Projections Moving into 2018

2018-09-14 09:10:00 | An Interview with Atossa CEO Steven Quay MD, Ph.D. Titled, _What Is Gynecomastia?_

2018-09-13 08:00:00 | Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen

2018-09-12 08:00:00 | Atossa Genetics to Host Conference Call to Announce Preliminary Results from Male Phase 1 Study of Topical Endoxifen Thursday, September 13, 2018 at 10 am EDT

2018-08-23 09:02:00 | ''Robust Economy, Resilient Market''

2018-08-21 09:05:00 | _What Is Intraductal Immuno-oncology & CAR-T Cell Therapy?_

2018-08-13 16:15:00 | Atossa Genetics Announces Second Quarter 2018 Financial Results And Provides Company Update

2018-08-01 09:05:00 | The Groundwork Forum Podcast Publishes _An Overview of Breast Cancer Treatment Innovator Atossa Genetics_